Teva recalls prazosin hydrochloride capsules over impurity above the acceptable limit
Test results for an impurity called N-nitroso Prazosin impurity C were above the acceptable intake limit for the recalled lots of prazosin hydrochloride capsules, which the notice calls a manufacturing practice deviation.
What to do
The notice does not give instructions. Read the official notice for details.
Note from Recalled Today: Don't stop taking a prescribed medicine before you talk to your pharmacist or doctor.
Recall details
- Product
- Prazosin Hydrochloride, Capsules, USP, 2 mg, Rx only, Distributed by TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, a) 100 Capsules, NDC 0093-4068-01, b) 1000 Capsules, NDC 0093-4068-10; Prazosin Hydrochloride, Capsules, USP, 1 mg, Rx only, Distributed by TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, a) 100 Capsules, NDC 0093-4067-01, b) 1000 Capsules, NDC 0093-4067-10; Prazosin…
- Hazard
- CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots.
- Units
- 291,512 bottles; 181,659 bottles; 107,673
- Where sold
- U.S. Nationwide
- FDA classification
- Class II · Ongoing
- Classified by FDA
- October 24, 2025
- Recall started
- October 7, 2025
- FDA enforcement report
- November 5, 2025
- Identifiers
- Codes: a) NDC 0093-4068-01: Lot # 3010398A, 3010399A, 3010400A, 3010401A, 3010353A, Exp Date: 12/2025; Lot # 3010439A, 3010388A, Exp Date: 01/2026; Lot # 3010526A, 3010527A, Exp Date: 03/2026; Lot # 3010591A, 07/2026; Lot # 3010343A, Exp Date: 10/2025; Lot # 3010352A, Exp Date: 11/2025; Lot # 3010468A, 3010469A, 3010461A, Exp Date: 02/2026; Lot # 3010629A, Exp Date: 09/2026; Lot # 3010653A, Exp Date: 01/2027; Lot # 3010654A, 3010679A, 3010702A, Exp Date: 02/2027; Lot # 3010547A, Exp Date: 04/2026 b) NDC 0093-4068-10: Lot # 3010402A Exp Date: 02/2028; Lot # 3010593A, Exp Date: 07/2026, Lot # 3010610A, Exp Date: 09/2026
- FDA recall number: D-0105-2026
- Codes: a) NDC 0093-4067-01: Lot # 3010544A and 3010545A, Exp Date: 10/2025; Lot # 3010567A, Exp Date: 12/2025; Lot # 3010590A, Exp Date: 02/2026; Lot # 3010601A, 3010602A, 3010603A, Exp Date: 03/2026; Lot # 3010652A, 3010670A, 3010671A, Exp Date: 07/2026; Lot # 3010678A, 3010700A, 3010701A, Exp Date: 08/2026 b) NDC 0093-4067-10: Lot # 3010440A, Exp Date: 12/2025; Lot # 3010672A, Exp Date: 07/2026
- FDA recall number: D-0104-2026
- Codes: a) NDC 0093-4069-01: Lot # 3010403A, 3010385A, 3010404A, Exp Date: 02/2026; Lot # 3010405A, 3010510A, 3010528A, 3010354A, Exp Date: 03/2026; Lot # 3010592A, 3010605A, 3010611A, 3010612A, Exp Date: 08/2026; Lot # 3010655A, 3010703A, Exp Date: 02/2027 b) NDC 0093-4069-52: Lot # 3010430A, Exp Date: 11/2025, Lot # 3010613A, Exp Date: 08/2026 c) NDC 0093-4069-05: Lot # 3010406A, Exp Date: 02/2026
- FDA recall number: D-0106-2026
The headline, summary and steps above are written in plain English from the official notice below. Identifiers are copied exactly as the agency published them. Always check the official notice before you act.
Official notice
The notice's own wording from FDA.
- Product
- Prazosin Hydrochloride, Capsules, USP, 2 mg, Rx only, Distributed by TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, a) 100 Capsules, NDC 0093-4068-01, b) 1000 Capsules, NDC 0093-4068-10 | Prazosin Hydrochloride, Capsules, USP, 1 mg, Rx only, Distributed by TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, a) 100 Capsules, NDC 0093-4067-01, b) 1000 Capsules, NDC 0093-4067-10 | Prazosin Hydrochloride, Capsules, USP, 5 mg, Rx only, Distributed by TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, a) 100 Capsules, NDC 0093-4069-01, b) 250 Capsules, NDC 0093-4069-52, c) 500 Capsules, NDC 0093-4069-05
- Reason for recall
- CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots.
- Classification
- Class II (Ongoing)
- Distribution
- U.S. Nationwide
- Quantity
- 291,512 bottles; 181,659 bottles; 107,673
Related recalls
Teva recalls isotretinoin capsules (30 mg and 40 mg) because some may be too strong or too weak
Some of the isotretinoin capsules were found to be either stronger or weaker than labeled, so patients may get more or less medicine than their prescription calls for.
Teva Pharmaceuticals USA, Inc · 30,360 units
Teva recalls Claravis isotretinoin 10 mg capsules because a drug impurity is above allowed limits
Some Claravis capsules tested above the allowed limit for an impurity called tretinoin, so they failed the company's quality checks for impurities and breakdown of the medicine.
Teva Pharmaceuticals USA, Inc · 5,101 cartons
Teva recalls Metoclopramide Tablets, USP, 5 mg over foreign tablets or capsules found in product
The notice says some bottles of these tablets contain foreign tablets or capsules, and it does not describe any effect on a person.
Teva Pharmaceuticals USA, Inc · 240,448 cartons
Amerisource Health Services recalls Prazosin Hydrochloride capsules over impurity above safe limit
The recalled prazosin hydrochloride capsules failed testing because they contain an N-nitroso Prazosin impurity C above the acceptable intake limit set under the CPCA approach.
Amerisource Health Services LLC · 7,198 units
Appco Pharma recalls prazosin hydrochloride capsules over impurity above acceptable limits
The 1mg, 2mg and 5mg capsules were found to contain a nitrosamine-related impurity, N-nitroso-prazosin impurity C, above acceptable limits.
Appco Pharma LLC · 175,061 units